The top U.S. infectious disease official said Gilead Sciences Inc's experimental antiviral drug remdesivir will become the standard of care for COVID-19 after early results from a key clinical trial on Wednesday showed it helped patients recover more quickly from the illness...
Show MoreKeep exploring
More to explore from shared collections and topics.
Contribute to BackpackerU Resources
Sign in to suggest resources and start organizing your own travel-learning library.